Search the Newsreel

Pfizer Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:PFE) 2026-08-04

This article provides access to the slide deck published by Pfizer Inc. in conjunction with their Q2 2026 earnings call. The report highlights that Pfizer's EPS of $0.77 beat expectations by $0.09, and revenue of $15.03 billion, up 2.60% year-over-year, beat by $645.82 million.

Pfizer Stock Slips Despite Earnings Beat and $2.5 Billion Cuts

This article first appeared on GuruFocus. Pfizer (NYSE:PFE), the pharmaceutical giant behind some of the world's biggest blockbuster drugs, edged about 0.5% lower in Tuesday's early trading despite delivering another earnings beat and raising its revenue outlook. The market appeared unconvinced that better quarterly …

Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts

Pfizer Inc. PFE used its second-quarter 2026 earnings call to stress that stronger non-COVID products are offsetting a weak infection season as investment targets oncology and obesity. Management raised the midpoint of full-year revenue guidance, expanded savings targets and reinforced the dividend. The call …

Company News for Aug 5, 2026

Allison Transmission Holdings Inc.'s (ALSN) shares surged 5.4% after reporting second-quarter 2026 adjusted earnings of $2.73 per share, surpassing the Zacks Consensus Estimate of $2.60 per share. Shares of The Clorox Co. (CLX) climbed 6.5% after posting fourth-quarter fiscal 2026 adjusted earnings of $1.66 …

Pfizer Covid Pill Revenue Plunges 95%. The Stock Is Rising Anyway.

Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand. Continue Reading

Pfizer (PFE) Stock Faces Pipeline Doubts After Higher Revenue Outlook

Pfizer Earnings Reveal New Engine Beyond Covid

This article first appeared on GuruFocus. Pfizer (NYSE:PFE) delivered stronger-than-expected second-quarter results as Specialty Care and newer acquired medicines offset continued weakness across Primary Care, reinforcing the company's transition away from pandemic-era products. The split matters because Pfizer's recovery increasingly depends on specialty drugs …

Pfizer beats earnings estimates, targets US$2.5 billion in additional cost cuts

Pfizer reported strong Q2 results, exceeding earnings estimates, driven by demand for Eliquis and acquired drugs. The company announced plans for an additional $2.5 billion in cost cuts, aiming for a total of $9.7 billion in net savings by 2029 to offset declining COVID-related …

Pfizer Earnings: Strong Growth for Newer Drugs Counters Covid Declines

Pfizer reported 3% revenue growth in the second quarter and maintained its adjusted diluted EPS guidance for 2026, leading to a 2% rise in shares. The company's newer drugs like Nurtec, Lorbrena, and Padcev are driving growth, offsetting reduced demand for COVID-19 products. Morningstar …

Pfizer Inc. Passt Gewinnprognose für 2026 an

PFE Q2 Earnings Top, 2026 Sales View Tweaked, COVID Forecast Cut

Pfizer PFEreported second-quarter 2026 adjusted earnings per share of 77 cents, which beat the Zacks Consensus Estimate of 68 cents per share. Earnings were flat year over year. Revenues came in at $15.03 billion, up 3% from the year-ago quarter on a reported basis …

Pfizer's Recovery Story Is Starting to Look More Durable

This article first appeared on GuruFocus. Pfizer Inc. (PFE, Financials), the pharmaceutical firm, said its second-quarter earnings topped Wall Street estimates and boosted its annual revenue guidance, as growth in its non-COVID portfolio compensated for a steep drop in Paxlovid sales.Adjusted earnings of 77 …

Pfizer Ducks Continued Covid Fallout As Hard-Fought Obesity Readout Looms

Pfizer beat second-quarter expectations Tuesday, offsetting a continued steep decline for its Covid products. But Pfizer stock fell. Continue Reading

Compared to Estimates, Pfizer (PFE) Q2 Earnings: A Look at Key Metrics

Pfizer (PFE) reported $15.03 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 2.6%. EPS of $0.77 for the same period compares to $0.78 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $14.45 billion, …

NYSE Content Update: ADI to Make NYSE Trading Debut After Spin-Off

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Aug. 4, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before …

Is Pfizer (PFE) A Bargain Following Its Earnings Beat And 2026 Guidance Lift?

Pfizer’s (NYSE:PFE) Q2 CY2026: Beats On Revenue

Pfizer's (NYSE:PFE) Q2 CY2026: Beats On Revenue Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 2.6% year on year to $15.03 billion. The company expects the full year's revenue to be around $61.5 billion, …

Pfizer (PFE) Reports Positive Phase 3 LITFULO Data In Vitiligo

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer (NYSE:PFE) reported positive Phase 3 results for LITFULO in nonsegmental vitiligo. The company plans to pursue global regulatory filings for LITFULO as …

Pharma-Zahlen im Kontrast: BioNTech schockt mit Prognose - Pfizer schafft die Überraschung

Pfizer Post Loss on Higher Revenue

Pfizer reported a second-quarter loss of $248 million, or 4 cents a share, despite a 3% increase in revenue to $15.03 billion. The company's revenue growth was driven by its oncology business, which helped to offset declining sales of its Covid-19 products. This contrasts …

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand. Continue Reading

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Focused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products(1) Advancing Robust Late-Stage Pipeline, with Several Key Pivotal Readouts Expected Over Next 12 Months Announces Expansion of Productivity Enhancement Initiatives NEW YORK, August 04, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results …

Caterpillar, Pfizer and 3 Stocks to Watch Heading Into Tuesday

As U.S. stock futures trade higher, several companies are poised for investor attention on Tuesday. Caterpillar (NYSE: CAT) and McDonald's (NYSE: MCD) are expected to report quarterly earnings, while Palantir Technologies (NASDAQ: PLTR), Snap Inc (NYSE: SNAP), and Pfizer Inc (NYSE: PFE) have already …

Pfizer raises revenue outlook after quarterly earnings top estimates

Pfizer beat Wall Street expectations for its second-quarter 2026 earnings and raised its full-year revenue guidance midpoint. The company reported adjusted earnings of $0.77 per share and revenue of $15.03 billion, driven by growth in new and acquired products, which offset declines in its …

Pfizer (PFE) Q2 Earnings and Revenues Top Estimates

Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs

Pfizer eleva su previsión de ventas para 2026 tras sólidos resultados trimestrales

Pfizer’s Quarterly Results Beat Expectations on Cancer, Heart Drugs

Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S Revenue Breakdown – NEO:PFE

This article provides a revenue breakdown for Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S (NEO:PFE). It highlights that the United States was the primary contributor to the company's revenue, generating ‪51.81 billion CAD last year and ‪53.01 billion CAD …

July Social Media Round-Up—America 250, Pfizer Futures, and More

This article provides a round-up of Pfizer's social media activities in July, highlighting various discussions, achievements, and scientific insights. It covers topics like living with alopecia areata, a Pfizer colleague's cancer survival story, and reflections on scientific advancements. The summary also notes leadership updates, …

Pfizer (PFE) Q2 Earnings: What To Expect

Pfizer (PFE) Q2 Earnings: What To Expect Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market hours. Here's what to expect. Pfizer beat analysts' revenue expectations last quarter, reporting revenues of $14.45 billion, up 5.4% year on year. It was …

ETFs Investing in Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs Stocks

This article lists ETFs that hold Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs stocks, highlighting one specific fund: the CTBC Global High Dividend ETF Securities Investment Trust Fund. It provides financial details such as market value, weight, issuer, management style, expense ratio, …

Pfizer (PFE) Stock Looks Reasonable Based On Today’s Broader Checks

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Pfizer stock has declined 27.7% over the past 5 years, yet the current valuation checks and market multiples now point to a picture that looks …

Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?

Pfizer offers an attractive 6.8% dividend yield and trades at 8.5x forward earnings, with a promising late-stage weight loss drug in its pipeline. Despite these positives, its stock has been stagnant due to recent negative revenue growth and upcoming patent expirations for key products …

Pfizer (NYSE: PFE) Offers Value And Income While Eli Lilly (NYSE: LLY) Bets On Growth In Diverging Pharma Investment Race

Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value and income play, the other stands out as a solid growth investment supported by rapid expansion in obesity and diabetes franchises. …

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have returned …